{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T10:01:52Z","timestamp":1768644112208,"version":"3.49.0"},"reference-count":28,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T00:00:00Z","timestamp":1736121600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100018688","name":"Korea Disease Control and Prevention Agency","doi-asserted-by":"publisher","award":["4845-300-210-13"],"award-info":[{"award-number":["4845-300-210-13"]}],"id":[{"id":"10.13039\/100018688","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Background: Botulinum neurotoxins (BoNTs), produced by Clostridium botulinum, are potent protein toxins that can cause botulism, which leads to death or neuroparalysis in humans by targeting the nervous system. BoNTs comprise three functional domains: a light-chain enzymatic domain (LC), a heavy-chain translocation domain (HCN), and a heavy-chain receptor-binding domain (HCC). The HCC domain is critical for binding to neuronal cell membrane receptors and facilitating BoNT internalization via endocytosis. Accordingly, it may serve as a vaccine candidate, inducing anti-BoNT-neutralizing antibodies in animals. Here, we aimed to develop a vaccine capable of simultaneously defending against both BoNT\/A and B. Methods: We combined the HCC domains of botulinum neurotoxin type A (BoNT\/A) and botulinum neurotoxin type B (BoNT\/B) in Escherichia coli to produce a recombinant protein (rHCCB-L-HCCArHCcB) that offers dual protection against both toxins by inhibiting their receptor binding. To evaluate the efficacy of the vaccine, mice were immunized intramuscularly with rHCCB-L-HCCA plus alum thrice at 2-week intervals, followed by the assessment of immunogenicity and protective efficacy. Results: The antibody titer in mice immunized with rHCCB-L-HCCA was significantly higher than that in mice immunized with alum alone, protecting them from the lethal challenges of BoNT\/A (105 50% lethal dose, LD50) and B (103 LD50). Conclusion: These findings suggest that rHCCB-L-HCCA may simultaneously be an effective vaccine candidate against BoNT\/A and B.<\/jats:p>","DOI":"10.3390\/vaccines13010039","type":"journal-article","created":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T08:08:52Z","timestamp":1736150932000},"page":"39","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Development of a Recombinant Fusion Vaccine Candidate Against Lethal Clostridium botulinum Neurotoxin Types A and B"],"prefix":"10.3390","volume":"13","author":[{"given":"Eun-Sun","family":"Choi","sequence":"first","affiliation":[{"name":"Division of High-Risk Pathogens, Department of Laboratory Diagnosis and Analysis, Korea Disease Control and Prevention Agency, KDCA, Cheongju 28159, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8775-3571","authenticated-orcid":false,"given":"Seong-Wook","family":"Pyo","sequence":"additional","affiliation":[{"name":"Division of High-Risk Pathogens, Department of Laboratory Diagnosis and Analysis, Korea Disease Control and Prevention Agency, KDCA, Cheongju 28159, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"So-Hyeon","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of High-Risk Pathogens, Department of Laboratory Diagnosis and Analysis, Korea Disease Control and Prevention Agency, KDCA, Cheongju 28159, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun-Ho","family":"Jeon","sequence":"additional","affiliation":[{"name":"Division of Infectious Disease Diagnosis, Chungcheong Regional Center for Disease Control and Prevention, Korea Disease Control and Prevention Agency, KDCA, Cheongju 28159, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gi-Eun","family":"Rhie","sequence":"additional","affiliation":[{"name":"Director General, Center for Vaccine Research, National Institute of Health, Korea Disease Control and Prevention Agency, KDCA, Cheongju 28159, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mi-Ran","family":"Yun","sequence":"additional","affiliation":[{"name":"Division of Infectious Disease Vaccine Research, Center for Vaccine Research, National Institute of Health, Korea Disease Control and Prevention Agency, KDCA, Cheongju 28159, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hwajung","family":"Yi","sequence":"additional","affiliation":[{"name":"Division of High-Risk Pathogens, Department of Laboratory Diagnosis and Analysis, Korea Disease Control and Prevention Agency, KDCA, Cheongju 28159, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4562-5533","authenticated-orcid":false,"given":"Yoon-Seok","family":"Chung","sequence":"additional","affiliation":[{"name":"Division of High-Risk Pathogens, Department of Laboratory Diagnosis and Analysis, Korea Disease Control and Prevention Agency, KDCA, Cheongju 28159, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,1,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1093\/infdis\/jiv327","article-title":"A novel botulinum neurotoxin, previously reported as Serotype H, has a hybrid-like structure with regions of similarity to the structures of Serotypes A and F and is neutralized with Serotype A antitoxin","volume":"213","author":"Maslanka","year":"2016","journal-title":"J. Infect. Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"14130","DOI":"10.1038\/ncomms14130","article-title":"Identification and characterization of a novel botulinum neurotoxin","volume":"8","author":"Zhang","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1001\/jama.285.8.1059","article-title":"Botulinum toxin as a biological weapon: Medical and public health management","volume":"285","author":"Arnon","year":"2001","journal-title":"JAMA"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1124\/pr.116.012658","article-title":"Botulinum neurotoxins: Biology, pharmacology, and toxicology","volume":"69","author":"Pirazzini","year":"2017","journal-title":"Pharmacol. Rev."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1038\/nature05411","article-title":"Structural basis of cell surface receptor recognition by botulinum neurotoxin B","volume":"444","author":"Chai","year":"2006","journal-title":"Nature"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1128\/CVI.00268-13","article-title":"The receptor binding domain of botulinum neurotoxin serotype A (BoNT\/A) inhibits BoNT\/A and BoNT\/E intoxications in vivo","volume":"20","author":"Diamant","year":"2013","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"794","DOI":"10.4161\/hv.9420","article-title":"Botulinum neurotoxin vaccines: Past history and recent developments","volume":"5","author":"Rusnak","year":"2009","journal-title":"Hum. Vaccines"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1146\/annurev.biochem.051908.125345","article-title":"Botulinum neurotoxin: A marvel of protein design","volume":"79","author":"Montal","year":"2010","journal-title":"Annu. Rev. Biochem."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1371\/journal.ppat.0030113","article-title":"Botulinum neurotoxin heavy chain belt as an intramolecular chaperone for the light chain","volume":"3","author":"Brunger","year":"2007","journal-title":"PLoS Pathog."},{"key":"ref_10","unstructured":"Centers for Disease Control and Prevention (1998). Botulism in the United States, 1899\u20131998. Handbook for Epidemiologists, Clinicians, and Laboratory Workers, Public Health Service, United States Department of Health and Human Services."},{"key":"ref_11","unstructured":"(2024, November 29). National Botulism Surveillance, Available online: https:\/\/www.cdc.gov\/botulism\/php\/national-botulism-surveillance\/index.html."},{"key":"ref_12","unstructured":"(2024, November 25). Infectious Disease Portal. Available online: https:\/\/dportal.kdca.go.kr\/pot\/is\/inftnsdsEDW.do."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"489","DOI":"10.3343\/alm.2021.41.5.489","article-title":"Genetic characterization of Clostridium botulinum isolated from the first case of infant botulism in Korea","volume":"41","author":"Jeon","year":"2021","journal-title":"Ann. Lab. Med."},{"key":"ref_14","first-page":"85","article-title":"Case of infant botulism in Texas","volume":"73","author":"Edmond","year":"1977","journal-title":"Tex. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jpeds.2022.08.016","article-title":"Dual-toxin (\u2018bivalent\u2019) infant botulism in California, 1976\u20132020: Epidemiologic, clinical, and laboratory aspects","volume":"253","author":"Panditrao","year":"2023","journal-title":"J. Pediatr."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1586\/erv.13.37","article-title":"What next for botulism vaccine development?","volume":"12","author":"Webb","year":"2013","journal-title":"Expert Rev. Vaccines"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jobb.2021.03.001","article-title":"Laboratory information management system for biosafety laboratory: Safety and efficiency","volume":"3","author":"Sun","year":"2021","journal-title":"J. Biosaf. Biosecur."},{"key":"ref_18","first-page":"27","article-title":"Purification of Clostridium botulinum type A neurotoxin","volume":"145","author":"Malizio","year":"2000","journal-title":"Methods Mol. Biol."},{"key":"ref_19","first-page":"169","article-title":"Enhancement of antibody-mediated botulinum toxin A neutralization by conjugating annexin V to the antibody in the mouse model","volume":"57","author":"Choi","year":"2021","journal-title":"Korea J Microbiol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1615\/CritRevImmunol.v27.i4.20","article-title":"Botulinum neurotoxin vaccines: Past, present, and future","volume":"27","author":"Smith","year":"2007","journal-title":"Crit. Rev. Immunol."},{"key":"ref_21","unstructured":"Centers for Disease Control and Prevention (CDC) (2011). Notice of CDC\u2019s discontinuation of investigational pentavalent (ABCDE) botulinum toxoid vaccine for workers at risk for occupational exposure to botulinum toxins. MMWR Morb. Mortal. Wkly Rep., 60, 1454\u20131455."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1080\/21645515.2015.1066051","article-title":"DNA vaccines targeting heavy chain C-terminal fragments of Clostridium botulinum neurotoxin serotypes A, B, and E induce potent humoral and cellular immunity and provide protection from lethal toxin challenge","volume":"11","author":"Scott","year":"2015","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/j.addr.2012.09.039","article-title":"Fusion protein linkers: Property, design and functionality","volume":"65","author":"Chen","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.pep.2008.04.013","article-title":"Increasing the homogeneity, stability and activity of human serum albumin and interferon-alpha2b fusion protein by linker engineering","volume":"61","author":"Zhao","year":"2008","journal-title":"Protein Expr. Purif."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s11095-008-9767-0","article-title":"Insertion of the designed helical linker led to increased expression of Tf-based fusion proteins","volume":"26","author":"Amet","year":"2009","journal-title":"Pharm. Res."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Ayyar, B.V., Tajhya, R.B., Beeton, C., and Atassi, Z. (2015). Antigenic sites on the HN domain of botulinum neurotoxin A stimulate protective antibody responses against active toxin. Sci. Rep., 5.","DOI":"10.1038\/srep15776"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"4305","DOI":"10.1128\/IAI.00405-09","article-title":"Antibody protection against botulinum neurotoxin intoxication in mice","volume":"77","author":"Cheng","year":"2009","journal-title":"Infect. Immun."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1016\/S0041-0101(98)00146-9","article-title":"Development of recombinant vaccines for botulinum neurotoxin","volume":"36","author":"Smith","year":"1998","journal-title":"Toxicon"}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/13\/1\/39\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T10:23:21Z","timestamp":1759919001000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/13\/1\/39"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,6]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1]]}},"alternative-id":["vaccines13010039"],"URL":"https:\/\/doi.org\/10.3390\/vaccines13010039","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,6]]}}}